Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · June 24, 2023

Befotertinib vs Icotinib as First-Line Therapy for Patients With EGFR-Mutated Locally Advanced or Metastatic Non–Small Cell Lung Cancer

The Lancet Respiratory Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Respiratory Medicine
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
Lancet Respir Med 2023 May 24;[EPub Ahead of Print], S Lu, J Zhou, H Jian, L Wu, Y Cheng, Y Fan, J Fang, G Chen, Z Zhang, D Lv, L Jiang, R Wu, X Jin, X Zhang, J Zhang, C Xie, G Sun, D Huang, J Cui, R Guo, Z Han, Z Chen, J Liang, W Zhuang, X Hu, A Zang, Y Zhang, S Cang, Y Lan, X Chen, L Liu, X Li, J Chen, R Ma, Y Guo, P Sun, P Tian, Y Pan, Z Liu, P Cao, L Ding, Y Wang, X Yuan, P Wu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading